Moberg Pharma announces issue of European Patent for Kerasal Nail

STOCKHOLM, May 28, 2015. Moberg Pharma AB (OMX: MOB) today announced that the
European Patent Office  has issued patent no. 2,777,689 for an improved
formulation of Moberg Pharma’s market-leading OTC product for the treatment of
fungal nails, sold in the U.S. under the Kerasal Nail® brand. The patent expires
in 2034.
The new European patent comprises composition of matter claims directed to novel
formulations for topical application to the nails. The corresponding U.S. patent
was also granted earlier this spring and Moberg Pharma is pursuing patent
approval in all major territories.

“The granted Kerasal Nail patents provide long-term intellectual property
protection for our flagship product. It also reconfirms our commitment to
bringing innovation to underserved niches and our long term goal to be the
leading player in nail fungus,” said Peter Wolpert, CEO of Moberg Pharma AB.

About Nail Fungus and Kerasal Nail®
Approximately 10% of the general population suffers from onychomycosis (nail
fungus) and a majority of those afflicted go untreated. Kerasal Nail® is an OTC
(over-the-counter) product based on a novel formulation of proven compounds and
is clinically proven to rapidly improve the appearance of unsightly fungal
nails. Kerasal Nail is applied to the damaged nail using a no-mess, silicone tip
applicator. Its efficacy and safety have been documented in several clinical
trials including more than 600 patients. Kerasal Nail has a unique rapid
mechanism of action and has demonstrated compelling treatment results, including
visible improvement within 2-4 weeks.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 8.30 a.m. (CET) on May 28, 2015.
For additional information contact:
Peter Wolpert, CEO, Telephone: +46 (0)70 - 735 7135, E-mail:
peter.wolpert@mobergpharma.se
Anna Ljung, CFO, Telephone: +46 (0)70 - 766 60 30, E-mail:
anna.ljung@mobergpharma.se
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
OTC sales operations in the U.S. and a distributor network in more than 40
countries. The company’s portfolio includes the OTC brands Kerasal®, Jointflex®,
Kerasal Nail®, Domeboro®, Vanquish®, and Fergon®. Kerasal Nail® (Emtrix® or
Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the
U.S., Canada and several EU markets and is currently being launched in Southeast
Asia. The company is growing organically as well as through acquisitions.
Internal development programs focuses on innovative drug delivery of proven
compounds and include two phase II assets, MOB-015 (onychomycosis) and BUPI
(oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the
company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic
Exchange Stockholm (OMX: MOB). For further information, please visit:
www.mobergpharma.com.